Acurx Pharmaceuticals, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares
Acurx Pharmaceuticals, Inc. (ACXP) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares of 1.40 million shares for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-11-10.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares · last filed 2022-11-10
- Acurx Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, vested, number of shares for the quarter ending 2022-09-30 was 149.54K shares, a 81.03% decline year-over-year.
- Acurx Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, vested, number of shares for the quarter ending 2022-06-30 was 156.42K shares, a 54.73% decline year-over-year.
- Acurx Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, vested, number of shares for the quarter ending 2022-03-31 was 1.10M shares.
- Acurx Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, vested, number of shares for the quarter ending 2021-09-30 was 788.17K shares.
- Acurx Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, vested, number of shares for fiscal 2021 was 930.83K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares 12 month |
|---|---|---|---|---|
| 2022-09-30 | 149.54K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | 305.96K shares derived: sum of 2 quarters · filed 2022-11-10 | 1.40M shares 10-Q · filed 2022-11-10 | |
| 2022-06-30 | 156.42K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | 1.25M shares 10-Q · filed 2022-08-12 | ||
| 2022-03-31 | 1.10M shares 10-Q · filed 2022-05-10 | |||
| 2021-12-31 | 930.83K shares 10-K · filed 2022-03-16 | |||
| 2021-09-30 | 788.17K shares 10-Q · filed 2021-11-12 | 1.13M shares derived: sum of 2 quarters · filed 2021-11-12 | ||
| 2021-06-30 | 345.50K shares 10-Q · filed 2021-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B |